+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Giant Cell Arteritis (GCA) Epidemiology Forecast - 2028

  • ID: 4871917
  • Report
  • December 2019
  • Region: Global
  • 80 pages
  • DelveInsight
1 of 2
'Giant Cell Arteritis (GCA) - Epidemiology Forecast - 2028' report delivers an in - depth understanding of the disease, historical & forecasted epidemiology of GCA in the 7 Major Markets (MM) i.e., United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2017 - 2028

Giant Cell Arteritis (GCA) - Disease Understanding

The Giant Cell Arteritis epidemiology report gives the thorough understanding of the GCA by including details such as disease definition, classification, symptoms, risk factors, pathogenesis, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Giant Cell Arteritis in the 7 Major Markets (MM), i.e., United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan. Giant cell arteritis (GCA) is an inflammatory disorder of medium - and large - size arteries affecting older people. Classically involved vascular sites include the external carotid branches, the ophthalmic, vertebral, distal subclavian, and axillary arteries as well as the aorta.

Giant Cell Arteritis (GCA) Epidemiology

The Giant Cell Arteritis (GCA) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major markets. The epidemiology data for Giant Cell Arteritis epidemiology are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Giant Cell Arteritis Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalence of Giant Cell Arteritis in 7MM, Sub - type specific prevalence of Giant Cell Arteritis, Gender Specific Diagnosed prevalence of Giant Cell Arteritis, Age Specific Diagnosed prevalence of Giant Cell Arteritis, Clinical Manifestations associated with Giant Cell Arteritis) scenario of Giant Cell Arteritis(GCA) in the 7MM covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017 - 2028.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to this research, Total prevalent population of Giant Cell Arteritis in 7 MM was observed to be 423,131 cases in 2017.

Report Scope
  • The report covers the descriptive overview of Giant Cell Arteritis , explaining its causes and currently available therapies
  • Comprehensive insight has been provided into the epidemiology of the Giant Cell Arteritis and its treatment in the 7 MM.
  • A detailed review of global historical and forecasted Giant Cell Arteritis epidemiology is included in the report, covering drug all 7 MM.
Giant Cell Arteritis Report Key Strengths
  • 10 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake
Giant Cell Arteritis Epidemiology Segmentation
  • Total prevalence of Giant Cell Arteritis in 7 MM
  • Sub - type specific prevalence of Giant Cell Arteritis in 7 MM
  • Gender Specific Diagnosed prevalence of Giant Cell Arteritis in 7 MM
  • Age Specific Diagnosed prevalence of Giant Cell Arteritis in 7 MM
  • Clinical Manifestations of Giant Cell Arteritis in 7 MM
Note: The publisher understands the needs of the rapidly changing market and the publisher is helping the client by providing the most up to date Report.
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Giant cell arteritis Market Overview at a Glance
2.1. Market Share (%) of Giant cell arteritis in 2017 - 7MM
2.2. Market Share (%) of Giant cell arteritis in 2028 - 7MM

3. Disease Background and Overview
3.1. Introduction
3.2. Etiology and risk factors
3.3. Signs and Symptoms associated with GCA
3.4. Pathophysiology
3.5. Clinical manifestations
3.6. Diagnosis
3.7. Molecular biomarkers in GCA patients important for diagnosis and prognosis

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent Cases of Giant Cell Arteritis in 7MM

5. Country Wise-Epidemiology
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalence of Giant Cell Arteritis in the United States
5.1.3. Sub-type specific prevalence of GCA in the United States
5.1.4. Gender Specific Diagnosed prevalence of GCA in the United States
5.1.5. Age Specific Diagnosed prevalence of GCA in the United States
5.1.6. Clinical Manifestations associated with GCA in the United States
5.2. EU-5
5.2.1. Assumptions and Rationale
5.2.2. Germany
5.2.3. France
5.2.4. Italy
5.2.5. Spain
5.2.6. United Kingdom
5.3. Japan
5.3.1. Assumptions and Rationale
5.3.2. Prevalence of Giant Cell Arteritis in Japan
5.3.3. Sub-type specific prevalence of GCA in Japan
5.3.4. Gender Specific Diagnosed prevalence of GCA in Japan
5.3.5. Age Specific Diagnosed prevalence of GCA in Japan
5.3.6. Clinical Manifestations associated with GCA in Japan

6. Treatment and Management
6.1. The new era for GCA: Biologic Agents
6.2. Patient Journey

7. Unmet needs

8. Appendix
8.1. Report Methodology

9. Publisher Capabilities

10. Disclaimer

11. About the Publisher
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll